STAR-VACCNCT07888647
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Overall Survival
Timeframe: Date of randomization to death from any cause, an average of 84 months.
Secondary (2)
Progression-free survival
Patient reported outcome
Arms and interventions
VaccinationExperimental
Patient in the Vaccination-Arm receives IDH1 peptide vaccine (IDH1-vac) with topical imiquimod (Aldara) and Temzolomid as background treatment.
Sham-VaccinationSham comparator
Patient in the Sham-Vaccination-Arm receives Immune stimulator (IS-vac) with topical imiquimod (Aldara) and Temzolomid as background treatment
Biologicals: IDH1-vac, IS-vac
Drugs: Temozolomide (TMZ), Imiquimod 5 % Cream
Sites
13 sites in 1 country